Directeur de recherche CNRS INMED, Institut de Neurobiologie de la Méditerranée, INSERM U901, Université d’Aix-Marseille.
A team of researchers from Inserm led by Pierre Szepetowski (INMED: “Institut de Neurobiologie de la Méditerranée” combined inserm/ University of Aix-Marseille unit) has just succeeded in identifying a gene whose mutations are responsible for a wide spectrum of epilepsies and epileptic encephalopathies with language dysfunction in children.
This work has been published in the journal “Nature Genetics”.
An epilepsy crisis is caused by sudden, short-lived, excessive activity of a group of neurons. It causes paroxysmal clinical symptoms, such as convulsions. Normally, epilepsy does not alter the cognitive capacities. However, in certain forms known as epileptic encephalopathies, the epileptic component can cause or worsen serious cognitive and behavioural problems (mental handicaps, language dysfunctions, autistic regression, etc.). This is the difference between these disorders and “conventional” epilepsy.
The team and the network of researchers led by Pierre Szepetowski tried to get a better understanding of the relationships between epilepsy and the numerous other problems related to the illness: autistic problems, cognitive problems, language dysfunction, speech impairment, dyslexia, voluntary movement disorders, migraines, etc.
Up until now, the cause of three rare forms of epilepsy and epileptic encephalopathies (acquired epileptic aphasia, continuous wave spike in slow sleep syndrome, and Rolandic epilepsy with speech disorders), had been under debate for over fifty years in the medical and scientific world and had remained unknown.
Thanks to a wide-ranging genetic analysis, the researchers, working as part of an extended network of epileptologists and scientists associating different hospitals and research centres , have just demonstrated that 20% of these cases of epilepsy often associated with language dysfunction have a common genetic cause. In all these forms of the disorder, there is mutation of the gene GRIN2A that codes for a glumatate receptor, a crucial neurotransmitter in the brain.
According to Pierre Szepetowski, this new light shed on the problem shows that “these three symptoms can be viewed as different clinical expressions of one and the same pathology at the crossroads between epilepsy, language dysfunction and cognitive and behavioural disorders”.
“These encephalopathies normally start around 4-5 years of age, after a period of normal development. Thereafter, development is variable and highly unpredictable. The identification of a first major cause will help us to better explain to parents how the disorder occurs, in particular for genetic counselling. We can also hope to see early therapeutic strategies set up in the future once we have a better understanding of the mechanisms. These will be crucial to improving the prognosis in cases of associated neuropsychological deficiencies”‘ adds Pierre Szepetowski.
Will in utero prevention of later epilepsy be possible one day?
During pregnancy, defects in the development of the cerebral cortex of the future baby can tigger subsequent epilepsy crises. Pierre Szepetowski’s team has just demonstrated that the absence of a protein known as Srpx2 disturbs the migration of neurons in the brains of developing rats. Even better, they succeeded in counter-acting these defects and their post-natal epileptic consequences in rats by administering Tubacin to the mother. Tubacin is capable of modifying the functioning of tubulins – molecules that are vital to building the architecture of neurons and to neuron migration.
These works, published in early July in the journal “Brain”, look like being a first step in the direction of theoretically preventing in utero the occurrence of certain types of epilepsy.
Inserm Unit U919, directed by Prof. Denis Vivien (“Serine Proteases and Physiopathology of the Neurovascular Unit”) has developed an antibody with potential therapeutic effects against multiple sclerosis. The study, directed by Fabian Docagne and published in Brain, paves the way for a ...
Doctors should rethink how they treat patients who have suffered the deadliest form of stroke, a clinical trial suggests.The study recommends a change in guidelines for treating any patients who have had a stroke caused by bleeding into the brain – known ...
GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction
Gaetan Lesca, Gabrielle Rudolf, Nadine Bruneau, Natalia Lozovaya, Audrey Labalme, Nadia Boutry-Kryza, Manal Salmi, Timur Tsintsadze, Laura Addis, Jacques Motte, Sukhvir Wright, Vera Tsintsadze, Anne Michel, Diane Doummar, Karine Lascelles, Lisa Strug, Patrick Waters, Julitta de Bellescize, Pascal Vrielynck, Anne de Saint Martin, Dorothee Ville, Philippe Ryvlin, Alexis Arzimanoglou, Edouard Hirsch, Angela Vincent, Deb Pal, Nail Burnashev, Damien Sanlaville, Pierre Szepetowski
Nature Genetics. 11 août 2013, http://dx.doi.org/10.1038/ng.2726
Tubacin prevents neuronal migration defects and epileptic activity caused by rat Srpx2 silencing in utero.
Manal Salmi, Nadine Bruneau, Jennifer Cillario, Natalia Lozovaya, Annick Massacrier, Emmanuelle Buhler, Robin Cloarec, Timur Tsintsadze, Françoise Watrin, Vera Tsintsadze, Céline Zimmer, Claude Villard, Daniel Lafitte, Carlos Cardoso, Lan Bao, Gaetan Lesca, Gabrielle Rudolf, Françoise Muscatelli, Vanessa Pauly, Ilgam Khalilov, Pascale Durbec, Yehezkel Ben-Ari, Nail Burnashev, Alfonso Represa, Pierre Szepetowski.
Brain. 2013 Jul 5 http://dx.doi.org/10.1093/brain/awt161